Physicians' Academy for Cardiovascular Education

SNAPSHOT: Novel interventions in CVD: Controversies & hot issues

May 7, 2013

Presentations & webcasts of this symposium will be posted soon

Novel interventions in cardiovascular disease: Controversies & hot issues


As a PACE member you are cordially invited to participate in our second PACE Snapshot meeting.

See updated agenda below

This PACE snapshot meeting is an initiative of the PACE foundation as part of its mission, which includes the review, exchange and assimilation of important new data underlying cardiovascular disease & diabetes and accelerate this information into clinical practice.

The aim of this meeting is to provide expert physicians with a state of the art and comprehensive overview of different novel interventions in the future management of cardiovascular disease, and a platform for discussion, debate and exchange.

The session is designed in a format with multiple short introductions by leading experts, covering a broad field of innovations in cardiovascular risk factor management, such as hypertension, lipid management, ACS, atrial fibrillation, anticoagulation and diabetes, including time for discussion and debate.
 

Meeting objectives

  • To review and discuss new data and developments on the pathophysiology of cardiovascular disease and its relevance to treatment strategies and outcomes.
  • To understand the pharmacologic and clinical rationale for various new treatment options in the management of cardiovascular disease.
  • To develop a consensus on practical guidelines for clinical management of the CHD disease patient.


Meeting Venue

Novotel Amsterdam City,  Europaboulevard 10, Amsterdam
 

Agenda

09:00 am – 12:30 hr (noon)

New concepts in management of CV Risk
09:05 – 09:20 - Cardiovascular management: What are the strategic changes?
John Deanfield, MD, London, United Kingdom

09:20 – 09:35 - The Inflammatory process and cardiovascular events: What are the targets for intervention?
Ulf Landmesser, MD, University Hospital Zurich, CH

Hypertension
09:35 – 09:50 - Update on therapy-resistant hypertension: novel pharmacotherapy or renal denervation?
Luis Ruilope, MD, Madrid, Spain

09:50 – 10:00 - Discussion
 
Innovations in LDL & HDL Cholesterol management
10:00 – 10:15 - New insights into the prevalence, phenotype and management of hoFH
Kees Hovingh, MD, Amsterdam, The Netherlands

10:15 – 10:30 - Lowering of LDL-C: Novel concepts and novel promises
Evan Stein, MD, Cincinnati, USA

10:30 – 10:40 - CETP inhibition: Where are we now?
John Kastelein, MD, Amsterdam, Nethetrlands

10:40 – 10:55 Targeting HDL-C: what are the options left?          
Bryan Brewer, MD, Washington DC, USA


10:55 – 11:10 - Discussion

Diabetes & cardiovascular disease
11:12 – 11:35 - Managing Diabetes to reduce cardiovascular outcomes: What’s new?
John Betteridge, MD, London, United Kingdom

Atrial Fibrillation & anticoagulation
11:25 – 11:40 - Atrial fibrillation & stroke prevention; What’s new?
John Camm, MD, London, UK
 
Breakthroughs in lipid management
11:40 – 11:50 - Targeting triglycerides: New insights from antisense therapy
Daniel Gaudet, MD, Québec, Canada

11:50 – 12:00 - HDL mimetics and plaque regression
Erik Stroes MD, Amsterdam, The Netherlands

12:00 – 12:10 - A novel approach to target fasting and postprandial triglycerides
Joanne M Donovan MD, Cambridge, MA, USA

12:10 – 12:30 - Discussion
 
12:30 - Lunch buffet & Adjourn
 

Registration

Participation to this session is limited and free for PACE members
For registration follow this link
 

Download the Invitation as PDF

Download Invite PACE Snapshot 2013 final.pdf


Funding

The PACE foundation acknowledges educational grants for support of this meeting from:
Pfizer Inc, Roche, AstraZeneca, Aegerion, ISIS pharmaceuticals, Catabasis Pharmaceuticals Inc, Cerenis therapeutics, Dezima Pharma
 

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.

Share this page with your colleagues and friends: